Rubraca (rucaparib) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration. Deprecated

Citation

Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf. Revised April 2018. Accessed October 6, 2026.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.	12

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
FDA (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib